Evaluation of the Reinforcing Strength of Phendimetrazine Using a Progressive-Ratio Schedule of Reinforcement in Rhesus Monkeys.
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
02
01
2020
accepted:
01
04
2020
pubmed:
10
4
2020
medline:
13
11
2020
entrez:
10
4
2020
Statut:
ppublish
Résumé
Stimulant abuse is a persistent public health problem with no Food and Drug Administration-approved pharmacotherapy. Although monoamine-releasing drugs such as
Identifiants
pubmed: 32269168
pii: jpet.120.264952
doi: 10.1124/jpet.120.264952
pmc: PMC7288731
doi:
Substances chimiques
Morpholines
0
Prodrugs
0
phendimetrazine
AB2794W8KV
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-5Subventions
Organisme : NIDA NIH HHS
ID : P50 DA006634
Pays : United States
Informations de copyright
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.
Références
Psychopharmacology (Berl). 2019 Sep;236(9):2569-2577
pubmed: 30900008
Neuropsychopharmacology. 2013 Feb;38(3):395-404
pubmed: 22968813
Psychopharmacology (Berl). 1996 May;125(1):13-22
pubmed: 8724444
Neuropsychopharmacology. 2013 Dec;38(13):2698-707
pubmed: 23893022
Curr Med Res Opin. 2008 May;24(5):1345-57
pubmed: 18384709
Psychopharmacology (Berl). 2009 Oct;206(3):447-56
pubmed: 19652955
Neuropsychopharmacology. 2011 Jan;36(2):539-47
pubmed: 20962765
Expert Opin Pharmacother. 2016 Dec;17(17):2307-2318
pubmed: 27734745
Drug Alcohol Depend. 2013 Aug 1;131(3):204-13
pubmed: 23726979
Neuroscience. 2016 Jun 2;324:367-76
pubmed: 26964683
J Neurosci Methods. 1996 May;66(1):1-11
pubmed: 8794935
J Pharmacol Exp Ther. 2009 Apr;329(1):272-81
pubmed: 19151247
Drug Alcohol Depend. 2003 May 1;70(1):39-52
pubmed: 12681524
J Addict Med. 2016 May-Jun;10(3):156-65
pubmed: 26933876
Eur J Pharmacol. 2002 Jun 28;447(1):51-7
pubmed: 12106802
Drug Alcohol Depend. 2013 Jun 1;130(1-3):158-66
pubmed: 23211394
Ann N Y Acad Sci. 2010 Feb;1187:76-100
pubmed: 20201847
Future Med Chem. 2012 Feb;4(2):245-65
pubmed: 22300101
Pharmacol Rev. 2011 Sep;63(3):750-71
pubmed: 21737530
Psychopharmacology (Berl). 2015 Jul;232(13):2405-14
pubmed: 25673020
Sci Rep. 2016 Aug 12;6:31385
pubmed: 27514281
Pharmacol Rev. 2016 Jul;68(3):533-62
pubmed: 27255266
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Behav Pharmacol. 1990;1(4):283-301
pubmed: 11175414
J Clin Psychopharmacol. 2001 Oct;21(5):522-6
pubmed: 11593078
J Pharmacol Exp Ther. 2007 Nov;323(2):599-605
pubmed: 17675585
Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27
pubmed: 20628632
Exp Clin Psychopharmacol. 2000 Aug;8(3):424-33
pubmed: 10975634
Cold Spring Harb Perspect Med. 2013 Jan 01;3(1):a012104
pubmed: 23125072
Alcohol Drug Res. 1987;7(5-6):351-61
pubmed: 3620005
Neuropsychopharmacology. 2015 Jul;40(8):1815-25
pubmed: 25563633
Psychopharmacology (Berl). 2010 May;209(4):375-82
pubmed: 20217052
Drug Alcohol Depend. 2009 Jan 1;99(1-3):261-71
pubmed: 18926645
Behav Pharmacol. 2011 Dec;22(8):824-36
pubmed: 22015808
Cell. 2015 Aug 13;162(4):712-25
pubmed: 26276628
Pharmacol Biochem Behav. 2016 Feb;141:58-65
pubmed: 26656213
Prog Brain Res. 2016;224:3-24
pubmed: 26822351